Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness of a quality improvement collaborative in reducing time to surgery for patients requiring emergency cholecystectomy.

BJS open·2019

Same author

Variation in outcomes and use of laparoscopy in elective inguinal hernia repair.

BJS open·2019

Same author

Validation of the acute cholecystectomy rate as a quality indicator for emergency general surgery using the SWORD database.

Annals of the Royal College of Surgeons of England·2019

Same author

Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

AJNR. American journal of neuroradiology·2019

Same author

Bladder and bowel continence in bilateral cerebral palsy: A population study.

Journal of pediatric urology·2016

Same author

Comparison of parental estimate of developmental age with measured IQ in children with neurodevelopmental disorders.

Child: care, health and development·2016

Search research articles

Related Experiment Video

Updated: May 7, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Acute thrombocytopenia after De-Nol.

I J Beckingham¹, G Baird, P J Kesteven

¹Department of Haematology, Freeman Hospital, Newcastle upon Tyne.

|July 1, 1989

Summary

A 72-year-old man developed severe acute thrombocytopenia after treatment with De-Nol (bismuth subcitrate potassium) for erosive biliary gastritis. This case highlights a potential adverse drug reaction requiring medical attention.

Area of Science:

Gastroenterology
Hematology
Pharmacology

Background:

Erosive biliary gastritis is a condition characterized by inflammation and erosion in the lining of the bile ducts.
De-Nol, containing bismuth subcitrate potassium, is a medication used to treat various gastrointestinal conditions, including peptic ulcers and gastritis.
Thrombocytopenia, a condition defined by a low platelet count, can arise from various causes, including medication side effects.

Observation:

A 72-year-old male patient was prescribed De-Nol for the management of erosive biliary gastritis.
Following the initiation of De-Nol therapy, the patient exhibited a significant and rapid decrease in platelet count, indicative of severe acute thrombocytopenia.

Findings:

The case report details a severe adverse drug reaction in a patient treated with De-Nol.

More Related Videos

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Related Experiment Videos

Last Updated: May 7, 2026

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells

Published on: December 27, 2017

Microfluidics in Assessing Platelet Function

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

The observed thrombocytopenia was directly linked to the administration of De-Nol, suggesting a potential causal relationship.

This event underscores the importance of monitoring platelet levels in patients undergoing treatment with De-Nol.

Implications:

Clinicians should be vigilant for the potential development of thrombocytopenia in patients receiving De-Nol, particularly those with pre-existing risk factors.
Prompt recognition and management of drug-induced thrombocytopenia are crucial to prevent serious complications.
Further research may be warranted to elucidate the precise mechanisms underlying De-Nol-associated thrombocytopenia and to establish clear guidelines for patient monitoring.